K
Kynexis
Precision therapeutics for cognitive impairment in schizophrenia
About Kynexis
Kynexis is a clinical-stage biotechnology company developing precision therapeutics for cognitive disorders, with lead candidate KYN-5356, a selective oral KAT-II (kynurenine aminotransferase II) inhibitor licensed from Mitsubishi Tanabe Pharma for cognitive impairment associated with schizophrenia (CIAS) and potential expansion into Alzheimer’s and other cognitive diseases. Founded in 2023 and headquartered in Naarden, Netherlands, with a US subsidiary in Cambridge, Massachusetts, it builds on research by scientific co-founders Dr Robert Schwarcz and Dr Carol Tamminga and is led by CEO Kees Been. After an initial €57 million Series A in 2023 led by Forbion, Ysios Capital and Sunstone Life Science Ventures, Kynexis in August 2026 closed a €40 million Series A extension led by Novartis Venture Fund with Forbion, Ysios and Sunstone returning—bringing total Series A financing to €97 million ($110 million)—to close out Phase 2 CIAS activities and prepare registrational development. Sources: company 19 Aug 2026; Forbion / PharmaLetter Aug 2026.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Nov 2023 | $63M | $251M | Ysios Capital · Sunstone Life Science Ventures · Forbion Capital Partners | ↗ |
Growth signals
Latest recorded traffic for Kynexis is 2.1K monthly website visits, up 740% over the last three months. Kynexis's team grew 144.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
TheremiaLeverage AI for inclusive healthcare |
Paris, France | Operational | 28 | $3.3M | $13M |
Moonlight AIThe company uses AI and machine learning to analyze genomic data |
Courroux, Switzerland | Operational | |||
Synamics TherapeuticsRedefining precision: innovating adaptive medicine through AI-powered solutions for intractable cancer |
Copenhagen, Denmark | Operational | |||
MI:RNA DiagnosticsVeterinary diagnostic testing using microRNA biomarkers and AI |
Whitburn, United Kingdom | Operational | |||
Scienta LabAI-powered Precision Immunology |
Gif-sur-Yvette, France | Operational | |||
IMU BiosciencesAI-powered platform decoding the immune system |
London, United Kingdom | Operational | |||
Ysotope TheranosticsTargeted radiopharmaceuticals for precision oncology |
Madrid, Spain | Operational | |||
Starget PharmaThis company is developing new targeted radiopharmaceutical technologies to treat solid tumors |
Ramat Hasharon, Israel | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Kynexis in the Naarden ecosystem
The Kynexis office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Forbion Capital Partners
Ysios Capital
Sunstone Life Science Ventures
Source: Dealroom Talent Intelligence.
See Kynexis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










